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Dyslipidemia and statin use have been associated with colorectal cancer (CRC), but prospective studies 
have shown mixed results. We aimed to determine whether dyslipidemia is causally linked to CRC risk 
using a Mendelian randomization approach and to explore the association of statins with CRC. A case-
control study was performed including 1336 CRC cases and 2744 controls (MCC-Spain). Subjects were 
administered an epidemiological questionnaire and were genotyped with an array which included 
polymorphisms associated with blood lipids levels, selected to avoid pleiotropy. Four genetic lipid 
scores specific for triglycerides (TG), high density lipoprotein cholesterol (HDL), low density lipoprotein 
cholesterol (LDL), or total cholesterol (TC) were created as the count of risk alleles. The genetic lipid 
scores were not associated with CRC. The ORs per 10 risk alleles, were for TG 0.91 (95%CI: 0.72–1.16, 
p = 0.44), for HDL 1.14 (95%CI: 0.95–1.37, p = 0.16), for LDL 0.97 (95%CI: 0.81–1.16, p = 0.73), and for 
TC 0.98 (95%CI: 0.84–1.17, p = 0.88). The LDL and TC genetic risk scores were associated with statin 
use, but not the HDL or TG. Statin use, overall, was a non-significant protective factor for CRC (OR 
0.84; 95%CI: 0.70–1.01, p = 0.060), but lipophilic statins were associated with a CRC risk reduction (OR 
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0.78; 95%CI 0.66–0.96, p = 0.018). Using the Mendelian randomization approach, our study does not 
support the hypothesis that lipid levels are associated with the risk of CRC. This study does not rule out, 
however, a possible protective effect of statins in CRC by a mechanism unrelated to lipid levels.
Colorectal cancer (CRC) has been associated with both genetic and environmental risk factors such as diet1,2, 
alcohol3, smoking4, physical activity5 and metabolic syndrome6,7. Metabolic syndrome is a cluster of important 
cardiovascular risk factors: high fasting glucose, abdominal obesity, high triglycerides (TG), reduced high density 
lipoprotein cholesterol (HDL) and high blood pressure. As one of the components, dyslipidemia has been thought 
to have an important role in inflammatory pathways, oxidative stress and insulin resistance, which could contrib-
ute to the pathogenesis of cancer. However, findings from prospective studies that have examined the association 
between serum dyslipidemia (TG, HDL, low density lipoprotein cholesterol (LDL) or total cholesterol (TC)) and 
colorectal neoplasia have been inconsistent6,8–11. It is unknown whether lipids and lipoproteins cause cancer or are 
intermediate or correlated factors within carcinogenic pathways. The Mendelian randomization approach can be 
used to establish a causal relationship between dyslipidemia and CRC. Mendelian randomization studies use the 
distribution of alleles in the population to simulate randomized assignment to lower or higher lipids. A previous 
Mendelian randomization analysis assessing the causality of dyslipidemia and CRC has been published before11. 
It reported an association between a genetic score for TC and the risk of CRC (OR per unit SD increase = 1.46; 
95% CI: 1.20–1.79) but no significant association was found for LDL, HDL or TG. While the association of TC 
was strong, the interpretation of the results is not straightforward, since TC is the sum of LDL and HDL choles-
terol, fractions that have been reported to have opposite effects regarding CRC and may explain the controversial 
findings of studies that have analyzed the association between high levels of serum TC and CRC risk8,9,12. A causal 
effect of lipids regarding CRC risk should have a clear mechanistic interpretation. Being TC essentially the sum 
of HLD and LDL, genetic instruments for TC are correlated either with LDL, HDL or both, which violates the 
pleiotropy assumption of Mendelian randomization studies.
Epidemiological studies on dyslipidemia and CRC risk could be confounded by 3-Hydroxy-
3-methylglutaryl-coenzyme A reductase inhibitors (statins) use, which might also have a protective effect on 
CRC. It is unclear whether it is statin use or dyslipidemia that prompted statin use, which may be associated 
with CRC. Indeed, a large number of epidemiological studies have examined the effect of statins on CRC risk, 
with often inconsistent results13,14. It has been suggested that pharmacogenetic variation or specific type of statin, 
which influence the effect on lipid levels, might also modify the statin-CRC risk association13–15.
In this study, we conducted a Mendelian randomization study to evaluate the relationship between CRC and a 
genetic risk score, derived from 119 genetic variants associated with blood concentrations of TG, HDL and LDL 
in GWAS studies. Moreover, we wanted to explore the effect of statins use on CRC.
Materials and Methods
Study population. A detailed description of the MCC-Spain case-control study has been provided else-
where16. Briefly, 10,183 subjects aged 20–85 years were enrolled in Spanish hospitals and primary care centers 
between 2008 and 2013. Eligible subjects included histological confirmed incident cases of CRC (n = 2,171). 
Both cases and controls were free of personal CRC history. For the present study we only have included a subset 
of 1,336 CRC cases and 2,744 controls that had genotype data. These subjects were selected from the complete 
study using a stratified random sampling strategy to maintain the distribution of cases and controls among par-
ticipating centers.
Data collection. A structured computerized epidemiological questionnaire was administered by trained per-
sonnel in a face-to-face interview. Subjects also filled in a semi-quantitative food frequency questionnaire, and 
blood samples and anthropometric data were obtained following the study protocol. This study did not collect or 
measured blood lipid levels for cases and controls.
The variables that were analyzed were those that could be related with CRC. We also wanted to explore var-
iables included in the definition of metabolic syndrome. So the variables considered for analyses were: level of 
education, family history of CRC (none versus first or second or third-degree); cigarette smoking (ever, never); 
average alcohol consumption between ages 30 and 40 (in standard units of alcohol, SUA, categorized into low-risk 
and high-risk consumption: >4 SUA/day in men and >2 SUA/day in women)17; diabetes (with only diet or 
using anti-diabetic drugs; hypertension (with only diet or antihypertensive treatment); body mass index (BMI), 
calculated with the weight reported at age 45, which was categorized according to World Health Organization 
criteria: underweight, normal weight, and overweight (<30 kg/m2) versus obese (≥30 kg/m2); abdominal obesity 
(calculated at the inclusion date) was defined according to World Health Organization criteria as a waist–hip 
ratio ≥ 0.90 cm for males and ≥0.85 cm for females; average physical exercise, determined using self-reported 
leisure-time activity performed in the past 10 years and used to estimate the Metabolic Equivalent of Task (MET) 
per hour per week, calculated using the Ainsworth’s compendium of physical activities18, and categorized as no 
physical activity in their leisure time (0 MET), and any physical activity in their spare time (>0 MET); vegetables, 
classified as low or high intake using 200 g/day as cut-off; red meat consumption including cured meat, and pro-
cessed meat. High intake of red meat was considered eating ≥65 g/day.
The location of the CRC was defined according to its anatomic distribution: proximal colon (colon above the 
level of the splenic flexure including it), distal (descending colon, sigmoid colon), and rectum.
All procedures performed in studies involving human participants were in accordance with the ethical stand-
ards of the institutional and/or national research committee and with the 1964 Helsinki declaration. The protocol 
of MCC-Spain was approved by each of the Ethics Committees of the participating institutions. The specific 
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study reported here was approved by the Bellvitge Hospital Ethics Committee with reference PR 149/08. Written 
informed consent was obtained from all individual participants included in the study.
Drug exposure. Use of prescription drugs was obtained through face-to-face interviews administered 
by trained personnel, mainly by indication. Information was coded following the Anatomical Therapeutic 
Chemical-ATC code to assess individual exposure to different drugs. All drugs prescribed to the patients were 
recorded, but only statins, aspirin (acetyl salicylic acid, ASA) or other nonsteroidal anti-inflammatory drugs 
(NSAIDs) were considered for this study. Statins were classified as lipophilic (atorvastatin, fluvastatin, lovastatin, 
simvastatin) or hydrophilic (pravastatin and rosuvastatin) and, by effectiveness in lowering LDL cholesterol lev-
els, as low-potency (fluvastatin, lovastatin, pravastatin, simvastatin) and high-potency (atorvastatin and rosuvas-
tatin)19. Moreover, statins users were considered regular if they started consuming these drugs at least one year 
before. Given that ASA or NSAIDs can be used sporadically, regular users were defined as consuming ≥1 time/
day for at least one year.
Genotyping and elaboration of genetic lipid scores. The Infinium Human Exome BeadChip 
(Illumina, San Diego, USA) array was used to genotype >200,000 coding markers plus 5000 additional custom 
single nucleotide polymorphisms (SNP) selected from previous genome-wide association studies (GWAS) or in 
genes of interest for cancer. SNPs associated with specific blood lipid levels (LDL, HDL, TG) in GWAS were iden-
tified through the GWAS catalogue20 and downloaded with the MRInstruments R package (https://github.com/
MRCIEU/MRInstruments). Retrieved SNPs were filtered according to these criteria: associated at genome-wide 
significance (p ≤ 5.0 × 10−8); restricted to Caucasian population; the allele associated with increased lipid level 
should be identified; only one SNP per chromosomal region (the most statistically significant SNP was selected 
when linkage disequilibrium was r2 > 0.2). To minimize pleiotropic effects, SNPs associated with more than one 
lipid trait (except for TC, which could share SNPs of HDL and LDL) or to other traits potentially related to 
CRC (alcohol, BMI, diabetes, inflammation) were excluded. SNP rs174546, which encodes for a protein that is a 
member of the fatty acid desaturase (FADS), was the only polymorphism that was associated with the three lipid 
pathways (an increase of LDL and HDL levels, but a decrease of TG), but many other SNPs were associated with 
more than one lipid trait. So, only SNPs exclusively associated at genome-wide significance with one lipid trait 
(either TG, HDL or LDL, but not more than 1) were chosen for each genetic risk score to make them as specific to 
one trait as possible (as in Holmes et al.21). To study total cholesterol (TC), since it was the sum of LDL and HDL, 
the SNPs selected were not restricted regarding pleiotropy22 between LDL and HDL (some selected SNPs may be 
related to both LDL and HDL). We consider the results for TC difficult to interpret, since LDL and HDL may have 
opposite effects. However, we provide the analysis for completeness and to compare the results with other studies.
Since the effects of each individual locus identified through GWAS are small, lipid genetic scores (LGS) were 
created as the joint additive effect of the selected SNPs risk alleles to increase the power of the Mendelian ran-
domization analysis23. We created four LGS: one for each lipid exposure of interest. Our exome array included 
22 SNPs associated with levels of TG, 36 with HDL, 39 with LDL and 49 with levels of TC, which are shown in 
Supplementary Table 1.
In all LGS, risk alleles were those associated with increase of TG, LDL, HDL or TC levels. Each SNP was coded 
according to the number of copies of the allele associated with dyslipidemia (0, 1, and 2) and each LGS was cre-
ated as the total sum of alleles across the specific SNPs for each lipid. To simplify the analyses, and because the 
effect size was not always reported or was in different units, an equal weight was assigned to all SNPs, though it is 
known that some SNPs show stronger associations with lipid levels than others.
Statistical analysis. Hardy-Weinberg equilibrium was tested among controls, and no SNP showed devia-
tion with p < 0.001. The sum of allele counts for each LGS was compared between cases and controls with linear 
models. Odds ratios (OR) and 95% confidence intervals (95% CI) were also calculated from logistic regression 
models. When referring to genetic scores, all ORs were scaled to express the risk per 10 alleles (OR10). A study 
design adjustment score (SDAS) was created to reduce bias related to differences in case and control selection 
frequencies. All the analyses were adjusted for this SDAS that included age, sex, recruiting center, level of edu-
cation and the three first principal components of genetic ancestry obtained from ancestry informative markers 
included in the genotyping array. The SDAS also included the interactions between age and sex, and region and 
sex. In addition to the SDAS, which was always considered, multivariate-adjusted models to assess the net effect 
of statins also included as potential confounders variables that were associated both with CRC (Table 1) and stat-
ins (Supplementary Table 2 shows the association of statin use with other variables among controls). To account 
for multiple comparisons when individual SNPs were analyzed, Bonferroni significance threshold were calcu-
lated (Supplementary Table 1). The SNPassoc24 package from R statistical software (R Foundation for Statistical 
Computing, Vienna, Austria) and PLINK25 were used for the analyses.
Statistical power. We performed a power calculation regarding the association of the LGS with CRC. We 
used the web application mRNd26 (https://cnsgenomics.shinyapps.io/mRnd), and assumed that the proportion 
of lipid levels variance explained by the LGS was 10%. Our study had 80% power to detect an OR of at least 1.33.
Results
In this population-based case-control study, as expected, CRC was associated with family history, high alco-
hol consumption, high waist-hip ratio, physical inactivity, low intake of vegetables, and high intake of red meat 
(Table 1). Regular AAS or NSAID use was associated with a reduced risk of CRC. Other covariates related with 
the metabolic syndrome such as diabetes mellitus and arterial hypertension were not associated with CRC.
Statin use was a borderline non-significant protective factor for CRC in the MCC-study in the multivariate 
analysis (OR = 0.84; 95% CI: 0.70–1.01, p = 0.060, Table 1). A total of 785 patients (535 controls and 250 CRC 
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cases) were current regular users of 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. The most 
frequently used was simvastatin (n = 373, 47.5% of users) followed by atorvastatin (n = 277, 35.3% of users).
Table 2 shows that only lipophilic statins (atorvastatin, fluvastatin, lovastatin, simvastatin), that were the 
most frequently used, were associated with a CRC risk reduction (OR = 0.79; 95% CI: 0.66–0.96, p = 0.016) but 
hydrophilic statins (pravastatin and rosuvastatin) did not. No differences were observed regarding lipid lowering 
potency. We also performed a stratified analysis to determine whether gender influenced the effect of statins 
on CRC. Statins had a stronger protective effect in men (adjusted OR = 0.80; 95% CI: 0.64–1.00 for men and 
OR = 0.92; 95% CI: 0.68–1.24 for women), but there was no sex interaction effect (P-value for interaction = 0.43). 
There was no effect modification when analyzing CRC location.
LDL genetic score and statins use. The LDL and TC LGS were associated with statin consumption among 
controls (OR10 = 2.12, 95% CI: 1.64–2.73, p < 0.0001 for LDL; OR10 = 1.67, 95% CI: 1.32–2.11, p < 0.0001 for TG). 






Crude ORa 95% CI P-value Adjusted ORb 95% CI P-valuen % n %
Age (years) at index date, median (IQR) 65 (56–72) 68 (60–76)
Male sex 1469 53.5 865 64.8
Family history of CRC 333 12.1 292 21.9 2.29 1.90–2.75 <0.0001 2.31 1.91–2.78 <0.0001
Cigarette smoking history 1549 56.5 779 58.3 1.20 1.04–1.38 0.01 1.07 0.93–1.24 0.34
High risk consumption alcohol 427 15.6 300 22.5 1.38 1.16–1.63 0.0002 1.31 1.10–1.56 0.0027
Diabetes mellitus 400 14.6 234 10.6 1.02 0.85–1.23 0.84 1.07 0.85–1.34 0.56
Arterial hypertension 1055 38.5 562 42.1 0.95 0.82–1.09 0.43 0.94 0.82–1.09 0.44
High waist–hip ratioc 1875 68.3 1082 81.0 1.34 1.13–1.59 0.0007 1.30 1.09–1.54 0.0032
Obesity (BMI ≥30 kg/m2) 188 6.9 142 10.6 1.36 1.07–1.73 0.01 1.29 1.04–1.64 0.043
Physical activity in leisure time 1057 38.5 619 46.3 0.73 0.63–0.84 <0.0001 0.74 0.65–0.80 0.0001
High intake of vegetables (>200 g/day) 846 30.8 345 25.8 0.72 0.62–0.84 <0.0001 0.75 0.64–0.88 0.0004
High intake of red meat (>65 g/day) 1123 40.9 674 50.5 1.38 1.20–1.59 <0.0001 1.30 1.13–1.50 0.0002
Regular ASA users 327 11.9 150 11.2 0.78 0.63–0.97 0.02 0.73 0.59–0.91 0.0060
Regular NSAIDs non-ASA users 422 15.4 122 9.1 0.56 0.45–0.69 <0.0001 0.59 0.47–0.74 <0.0001
Regular statin users 535 19.6 250 18.7 0.81 0.68–0.96 0.02 0.84 0.70–1.01 0.060
Table 1. Characteristics of the MCC-Spain study participants and association of every risk factor with CRC. 
ASA: acetylsalicylic acid; BMI: body mass index; MET: Metabolic equivalent of task (MET) per hour per week; 
NSAID: Nonsteroidal Anti-inflammatory Drugs. aORs and 95% CI derived from logistic regression models 
adjusted for the study design factors (age, sex, center and education). bEach variable adjusted for the study 
design adjustment and potential confounders for statin use (alcohol, waist-hip ratio, physical activity, read meat 
and ASA or NSAIDs). c≥ 0.90 cm (men); ≥0.85 cm (women).
Controls CRC cases
Adjusted 






Lipophilicity Non-users 2209 80.5 1086 81.3 1.00
Lipophilic 508 18.5 223 16.7 0.79 0.66–0.96 0.016
Hydrophilic 26 0.9 26 1.9 1.69 0.94–3.04 0.077
Potency Non-users 2209 80.5 1086 81.3 1.00
Low 346 12.6 154 11.5 0.82 0.66–1.01 0.066
High 189 6.9 96 7.2 0.88 0.66–1.16 0.38
Subgroup analysis
Gender Non-users 1087 67.0 382 60.4 1.00
Female 188 11.6 89 14.1 0.92 0.68–1.24 0.58
Male 347 21.4 161 25.4 0.80 0.64–1.00 0.046
Cancer location Non-users 2209 80.5 626 73.1 1.00
Colon 535 19.5 144 16.8 0.86 0.69–1.06 0.16
Rectum 86 10.0 0.81 0.62–1.06 0.13
Table 2. Statin use and CRC risk. a% of statin users over total number in subgroup. bORs and 95% CI derived 
from logistic regression models adjusted for the study design factors (age, sex, center and education), alcohol, 
waist-hip ratio, physical activity, red meat, and ASA or NSAID use.
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of the LDL LGS. The figure shows that this increase was linear, indicating an independent additive contribution 
of each SNP to the LDL score. Each risk allele increased a 7.8% the likelihood of being a regular statin user. This 
association was similar in cases. Though blood lipid levels for the subjects were not collected in the MCC study, 
this observation supports the validity of the LDL LGS used as an instrumental variable for lifetime exposure to 
higher LDL levels. HDL and TG LGS were not associated with statin use (OR10 = 1.10, 95%CI: 0.86–1.42, p = 0.49 
for HDL and OR10 = 1.33, 95%CI: 0.96–1.84, p = 0.092 for TG).
Association of lipid genetic scores with CRC. None of the SNPs contributing to each of the LGS 
was associated with CRC when Bonferroni correction was applied (see Supplementary Tables 1–4 for details). 
Moreover, the distribution of estimated risk effects showed a normal distribution around an average of zero, with 
some SNPs showing a direct association with CRC while others had an inverse direction, suggesting that the 
observed effects were likely related to random variation. The most significant SNPs in relation with CRC in our 
population were rs1748195 for TG, rs7941030 for HDL, rs12916, rs10102164 and rs10102164 for LDL. For TC, 
the most significant SNPs were rs12916, rs10102164 and rs7941030 which also were related to LDL and HDL, as 
expected.
None of the Mendelian randomization estimates for the associations between LGS and CRC, based on 
unweighted allele scores, show any risk effect (Table 3). Cases had the same average risk alleles than controls 
in all the lipids traits (Table 3 and Fig. 2). Therefore, individuals with larger numbers of TG, HDL, LDL, or TC 
risk alleles were not at higher risk for CRC. Also, since the LDL and TC LGS were associated with statin use, we 
performed the analysis stratified by statin use. As Table 3 shows, the instruments were not associated with CRC 
among non-users of statins and there was not an effect interaction. Furthermore, to discard the possibility of con-
founding or pleiotropy, we confirmed that the LGS were independent of known CRC risk factors (Supplementary 
Table 5), and specifically discarded effect modification by BMI, diabetes or hypertension.
Discussion
Mendelian randomization is a technique used to determine the causal impact of a risk factor on an outcome from 
observational data using genetic variants. It has already been used to investigate associations between blood lipids 
and colorectal polyps27, coronary heart disease28, and prostate cancer29. In our study, using the Mendelian rand-
omization approach, none of the lipid genetic scores for dyslipidemia analyzed was associated with CRC risk. This 
indicates that lifetime dyslipidemia most probably is unrelated to the development of colorectal neoplasms, and 
that the associations previously found in observational studies between dyslipidemia and CRC could be result of 
uncontrolled confounding factors or reverse causation.
This analysis was based on the usual instrumental variable assumptions of Mendelian randomization studies 
that use genetic scores as lifetime exposure surrogates. The first assumption was that the LGS was associated with 
the exposure of interest. Our study could not test this condition directly since lipid levels were not measured, 
but it was probably fulfilled, since we selected SNPs that had been linked to plasma lipid levels in GWAS20. As an 
indirect check of this assumption, we confirmed the association between the TC, LDL and TG allele score and 
statin consumption, a drug that is essentially prescribed for high LDL but also for hypertriglyceridemia30,31. The 
second assumption was that the LGS was not related to other factors that confound the exposure-outcome rela-
tionship. Potential confounding factors (diabetes mellitus, arterial hypertension, BMI, and waist–hip ratio) that 
could influence the relationship between dyslipidemia and CRC were explored, and none were associated with 
Figure 1. LDL LGS and statin use (Controls only). The black dots follow the left axis scale and correspond to 
the OR for statin use according to the number of LDL LGS risk alleles. The reference group is the median in the 
population, or subjects with 41–43 risk alleles. The green line corresponds to a linear model fitted to the ORs, to 
emphasize the linear relationship that can be interpreted as independent contribution of each SNP to the LDL 
LGS. Each risk allele increases 7.8% the likelihood of being regular statin user. The bars follow the right axis 
scale and indicate the proportion of users (red) and non-users (gray) for each allele count grouping.
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the LGS. We acknowledge, however, that the existence of residual confounding cannot completely be ruled out in 
a case-control study. Since the genetic scores were related to statin use, we also performed an analysis stratified 
by use of these drugs and observed no effect modification. Mendelian randomization studies are usually robust 
to confounding, as long as the third assumption is met: the effect of the LGS on the outcome should be mediated 
only through the association with the modifiable risk factor. We cannot rule out pleiotropic effects of the SNPs 
included in the LGS that may confound the association, though we carefully selected the SNPs to avoid that. 
We excluded SNPs associated with other traits than the lipid of interest. In fact, these strong assumptions that 
Mendelian randomization studies require are suggested to be the reason why this type of study may find more 
negative results22,23.
It is uncertain whether dyslipidemia may contribute to the pathogenesis of colorectal neoplasia. In fact, three 
recent meta-analysis/systematic reviews show controversial results. Yao et al.8, concluded that especially high 
levels of TG and TC were associated with an increased risk of CRC, whereas HDL might be associated with a 
decreased risk of CRC. In contrast, Tian et al.9 reported that high levels of TC, TG and LDL were associated with 
colorectal adenoma but not with CRC, and no association was observed between levels HDL and colorectal neo-
plasia. Finally, Passarelli et al.12 found a 13% higher prevalence of colorectal adenomas per increase in TG levels 
at colonoscopy, a 4% lower per increase in HDL and similar blood concentrations of LDL and TC. There are two 
studies based on Mendelian randomization to assess the causality of dyslipidemia and colorectal neoplasia11,27. 
Passarelli et al.27 investigated the relationship between dyslipidemia and polyps and they reported that genotype–
polyp odds ratio using weighted allele scores were not associated On the other hand, Rodriguez-Broadbent et 
al.11 supported a causal relationship between higher levels of TC with CRC risk. In our study, we did not find any 
association between dyslipidemia, including TC, and CRC. We have explored the relationship between TC and 
CRC and found it unrelated, though we believe its interpretation can be difficult as TC is essentially the sum of 
LDL and HDL and HDL may have an inverse effect on risk as it has been suggested for cardiovascular diseases32.
Regarding statins, these drugs have been suggested to play a role in cancer chemoprevention33,34. However, 
epidemiological evidence remains inconclusive. Recently, two meta-analyses including 40 and 42 individual stud-
ies, respectively13,14, reported a modest reduction in risk of CRC among statin users, though this was only among 
cohort studies and case control studies, and not among randomized controlled trials. It is unclear whether statin 
use may be associated with CRC due to their lipid lowering activity or to other mechanisms. Also, the association 
of statins with CRC could be just a reflection of the possible risk associated with high lipid levels. Confounding by 
indication is a common bias in observational studies and occurs when the indication (high cholesterol) for the med-
ication under study (statin) is also associated with the outcome of interest (CRC). We have found that statin use was 
associated with CRC, with a borderline non-significant risk reduction of 16% in the multivariate adjusted model. 
However, we admit with a point estimate of 0.84 and a confidence interval which goes from 0.70 to 1.01, data must 
be interpreted cautiously. The failure to obtain a significant association could be related to statistical power, because 
our study is large, but not huge. We found, however, a stronger risk reduction for lipophilic statins. It is known that 
lipophilic statins show an efficient activity both at hepatic and extrahepatic sites, which could explain a higher effect 
in colonic tissue35. Since statins show a probable risk reduction of CRC but our Mendelian randomization study 
rules out the role of lipids, we should consider that the protective effect of statins is related to other mechanisms of 
action independent of lipid levels, such as anti-inflammatory effects36 or microbiome interactions37.
Although our study does not support a causal effect of dyslipidemia in CRC risk, we must consider that 







alleles 95% CI P-valueMean ± sd Mean ± sd
TG 23.44 ± 2.91 23.34 ± 2.82 0.91 0.72–1.16 0.44
HDL 38.05 ± 3.75 38.13 ± 3.75 1.14 0.95–1.37 0.16
LDL 40.71 ± 3.80 40.69 ± 3.80 0.97 0.81–1.16 0.73
TC 49.06 ± 4.11 49.00 ± 4.07 0.99 0.84–1.17 0.89
Statins non-users
TG 23.40 ± 2.90 23.28 ± 2.83 0.90 0.69–1.18 0.46
HDL 38.04 ± 3.81 38.17 ± 3.72 1.20 0.98–1.47 0.076
LDL 40.50 ± 3.79 40.58 ± 3.75 1.06 0.87–1.30 0.56
TC 48.91 ± 4.08 48.86 ± 4.03 1.03 0.85–1.25 0.76
Statins users
TG 23.62 ± 2.93 23.56 ± 2.74 0.99 0.58–1.71 0.98
HDL 38.13 ± 3.50 37.95 ± 3.92 0.91 0.59–1.39 0.64
LDL 41.57 ± 3.74 41.19 ± 3.97 0.74 0.49–1.12 0.15
TC 49.72 ± 4.17 49.59 ± 4.17 0.91 0.63–1.32 0.63
Table 3. Association of lipid genetic scores with CRC. TG: triglycerides; HDL: high density lipoprotein 
cholesterol; LDL: low density lipoprotein cholesterol; TC: total cholesterol. All genetic scores are coded as 
increasing lipid levels. aORs and 95% CI derived from logistic regression models adjusted for the study design 
factors (age, sex, center and education). The quantitative genetic score calculated as the sum of risk alleles was 
divided by 10.
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explained above, may not be fully met. Also, the modest sample size of our study results in a limited statistical 
power for a Mendelian randomization study unless the magnitude of the association is large26,38. Our calculations 
indicate that we have good power to detect OR > 1.33, assuming that the proportion of explained variance in lipid 
levels by the genetic score is 10%, which is debatable, but seems reasonable according to previous literature39. We 
assigned equal weight to each SNP, which may be suboptimal, but was necessary to include in the LGS some SNPs 
for which the effect size was unreported or were expressed in different units. Another important limitation is that 
we do not have serum lipid levels. However, the fact that the instrumental variable estimation for the LDL levels 
was associated with statins use supports the validity of the score used.
In conclusion, the null association observed in this Mendelian Randomization study does not support the 
hypothesis that dyslipidemia is involved in the pathogenesis of CRC. Our study found that lipophilic statins could 
have a possible protective effect on CRC by a mechanism unrelated to lipid levels.
Data Availability
The datasets generated and/or analyzed during the current study are not publicly available as they contain infor-
mation that could compromise the privacy of research participants. The data are available from the corresponding 
author on request, but access to the data is dependent on consideration of the request by the Study Direction 
Committee, which serves as the data access committee for this study. The committee is affiliated to CIBER of 
Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid.
Figure 2. Distribution of the genetic risk score of every lipid trait in cases and controls. The x-axis indicates 
the number of risk alleles of the lipid genetic risk score indicated in each figure title. The y-axis corresponds 
to the proportion of subjects observed for each risk allele count. The proportion of controls are shown in gray 
and, superimposed, the proportion of cases in red. Deviations from the overlap between cases and controls are 
shown in light color. The distributions do not differ in shape or location as indicated in the t-tests performed to 
compare the number of risk alleles between cases and controls.
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